Skip to main content
ACG 2025 Annual Meeting Main banner
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Award Winner
ACG Newsworthy Abstract
ACG Newsworthy Abstract
Registration Required
Registration Required
No CME
No CME
On-Demand Video
On-Demand Video
Livestream
Livestream

Monday Poster Session

Category: Colon

P2406 - Clinical Outcomes of Sodium Sulfate Tablets vs PEG-Based Solutions for Inpatient Colonoscopy Preparation: A Propensity-Matched Analysis

Monday, October 27, 2025
10:30 AM - 4:00 PM MT
Location: Exhibit Hall
Rakahn Haddadin, MD1, Carol Monis, MD2, Eric H. Choi, MD, FACG2
1HCA Healthcare MountainView Hospital, Las Vegas, NV; 2HCA Healthcare Riverside Community Hospital, Riverside, CA

Introduction: Bowel preparation in hospitalized patients is frequently inadequate due to limited mobility, nausea, and comorbid conditions. Sodium sulfate tablets (Sutab) offer a low-volume alternative that may be better tolerated than traditional polyethylene glycol (PEG)-based solutions such as GoLYTELY and MoviPrep. This study compared procedural success and clinical outcomes of inpatients receiving Sutab versus GoLYTELY or MoviPrep prior to colonoscopy.

Methods: We conducted a retrospective cohort study using the TriNetX health research network across 67 U.S. healthcare organizations. Adult inpatients undergoing colonoscopy who received Sutab, GoLYTELY, or MoviPrep were identified. Propensity score matching was performed to balance demographics and comorbidities. The primary outcomes were colonoscopy completion and poor bowel preparation. Secondary outcomes included acute kidney injury (AKI), blood transfusion, aspiration pneumonia, mortality, and CTA abdomen utilization. (Table 1). Sutab was the only small volume preparation available for data analysis. GoLYTELY and Moviprep were the main preparations used in hospital settings according to TRINETX data.

Results:

After matching, 25,919 Sutab-GoLYTELY pairs and 11,922 Sutab-Moviprep pairs were analyzed. Compared to GoLYTELY, Sutab was associated with higher colonoscopy completion rates (35.6% vs. 26.6%, p< 0.001), and lower rates of AKI (2.7% vs. 7.0%), transfusion (0.6% vs. 2.9%), aspiration pneumonia (0.3% vs. 0.8%), and death (0.9% vs. 3.4%) (all p< 0.001). Poor preparation rates were low in both groups (0.3% vs. 0.4%, p=0.025). (Table 2)

Compared to MoviPrep, Sutab again showed superior colonoscopy completion (36.8% vs. 23.5%, p< 0.001), with lower rates of AKI (3.7% vs. 17.3%), transfusion (0.7% vs. 10.1%), aspiration pneumonia (0.3% vs. 2.4%), and death (1.2% vs. 6.3%) (all p< 0.001). Poor prep rates were also reduced with Sutab (0.3% vs. 0.8%, p< 0.001). (Table 2)

Discussion: Among hospitalized patients, Sutab demonstrated significantly improved procedural success and reduced adverse clinical outcomes compared to both GoLYTELY and MoviPrep. These findings suggest that Sutab may offer a more effective and safer bowel preparation strategy in inpatient settings. Hospitals should consider including Sutab in formularies to enhance colonoscopy readiness and minimize complications in this vulnerable population.


Figure: Table 1: Patient Demographics


Figure: Table 2: Study Data

Disclosures:
Rakahn Haddadin indicated no relevant financial relationships.
Carol Monis indicated no relevant financial relationships.
Eric H. Choi indicated no relevant financial relationships.

Rakahn Haddadin, MD1, Carol Monis, MD2, Eric H. Choi, MD, FACG2. P2406 - Clinical Outcomes of Sodium Sulfate Tablets vs PEG-Based Solutions for Inpatient Colonoscopy Preparation: A Propensity-Matched Analysis, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.